Calidi Biotherapeutics Management

Management criteria checks 4/4

Calidi Biotherapeutics' CEO is Allan Camaisa, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $436.51K, comprised of 58.9% salary and 41.1% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $148.05K. The average tenure of the management team and the board of directors is 6.8 years and 3.8 years respectively.

Key information

Allan Camaisa

Chief executive officer

US$436.5k

Total compensation

CEO salary percentage	58.9%
CEO tenure	6.8yrs
CEO ownership	0.4%
Management average tenure	6.8yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Allan Camaisa's remuneration changed compared to Calidi Biotherapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$437k	US$257k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$43k	-US$25m
Sep 30 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$26k	-US$11m

Compensation vs Market: Allan's total compensation ($USD436.51K) is below average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Allan's compensation has been consistent with company performance over the past year.

CEO

Allan Camaisa (64 yo)

6.8yrs

Tenure

US$436,512

Compensation

Mr. Allan J. Camaisa serves as Chief Executive Officer and Chairman of the Board at Calidi Biotherapeutics, Inc since February 2018. He served as Chief Executive Officer and Chairman at Parallel 6, Inc. si...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
Wendy Pizarro Campbell	Chief Administrative Officer	3.2yrs	US$295.40k	0.084% $ 31.3k
Boris Minev	President of Medical & Scientific Affairs and Interim Chief Medical Officer	9.4yrs	US$400.10k	0.22% $ 81.9k
Andrew Jackson	Chief Financial Officer	1.1yrs	no data	no data
Stephen Thesing	Chief Business Officer	8.8yrs	no data	0.24% $ 91.0k

6.8yrs

Average Tenure

58yo

Average Age

Experienced Management: CLDI's management team is seasoned and experienced (6.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
James Schoeneck	Independent Director	4.3yrs	US$109.56k	0.53% $ 197.4k
W.K. Yung	Member of Medical Advisory Board	2.4yrs	no data	no data
Ewa Carrier	Member of Medical Advisory Board	no data	no data	no data
George Peoples	Independent Director	less than a year	no data	0.00089% $ 331.8
Scott Leftwich	Independent Vice-Chairman of the Board	5.5yrs	US$179.89k	1.23% $ 459.1k
Alan Stewart	Independent Director	1.1yrs	US$120.56k	0.029% $ 10.7k
Santosh Kesari	Member of Medical Advisory Board	no data	no data	no data
Dmitriy Zamarin	Member of Scientific Advisory Board	3.8yrs	no data	no data
Ashok Srivastava	Member of Scientific Advisory Board	no data	no data	no data
Karen Aboody	Member of Medical Advisory Board	no data	no data	no data
Maciej Lesniak	Member of Medical Advisory Board	no data	no data	no data

3.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: CLDI's board of directors are considered experienced (3.8 years average tenure).

Calidi Biotherapeutics Management

Management criteria checks 4/4

Key information

Recent management updates

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age